Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share

Earnings Per Share

3 Months Ended

Mar. 31, 2021

NOTE 9 – EARNINGS PER SHARE

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings (loss) per share (EPS) computations.

Basic and diluted earnings (loss) per share are the same since net losses for all periods presented and including the additional potential common shares would have an anti-dilutive effect.

The following table sets forth the computation of basic and diluted net income per share:

	Three Months Ended March 31, 2021
	2021			2020
Net loss attributable to the common stockholders	$	(461,682	)	$	(251,182	)

Basic weighted average outstanding shares of common stock		35,241,202			500,000
Dilutive effect of options and warrants		—			—
Diluted weighted average common stock and common stock equivalents		35,241,202			500,000

Loss per share:
Basic and diluted	$	(0.01	)	$	(0.50	)